219 related articles for article (PubMed ID: 35511749)
1. A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.
Fernández-Rodríguez J; Creus-Bachiller E; Zhang X; Martínez-Iniesta M; Ortega-Bertran S; Guha R; Thomas CJ; Wallace MR; Romagosa C; Salazar-Huayna L; Reilly KM; Blakely JO; Serra-Musach J; Pujana MA; Serra E; Villanueva A; Ferrer M; Lázaro C
Mol Cancer Ther; 2022 Jul; 21(7):1246-1258. PubMed ID: 35511749
[TBL] [Abstract][Full Text] [Related]
2. Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities.
Creus-Bachiller E; Fernández-Rodríguez J; Magallón-Lorenz M; Ortega-Bertran S; Navas-Rutete S; Romagosa C; Silva TM; Pané M; Estival A; Perez Sidelnikova D; Morell M; Mazuelas H; Carrió M; Lausová T; Reuss D; Gel B; Villanueva A; Serra E; Lázaro C
Mol Oncol; 2024 Apr; 18(4):895-917. PubMed ID: 37798904
[TBL] [Abstract][Full Text] [Related]
3. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
[TBL] [Abstract][Full Text] [Related]
4. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
5. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
Borcherding DC; Amin NV; He K; Zhang X; Lyu Y; Dehner C; Bhatia H; Gothra A; Daud L; Ruminski P; Pratilas CA; Pollard K; Sundby T; Widemann BC; Hirbe AC
Clin Cancer Res; 2023 Apr; 29(8):1592-1604. PubMed ID: 36799629
[TBL] [Abstract][Full Text] [Related]
6. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
[TBL] [Abstract][Full Text] [Related]
7. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
8. Malignant peripheral nerve sheath tumor: models, biology, and translation.
Somatilaka BN; Sadek A; McKay RM; Le LQ
Oncogene; 2022 Apr; 41(17):2405-2421. PubMed ID: 35393544
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine.
Castellsagué J; Gel B; Fernández-Rodríguez J; Llatjós R; Blanco I; Benavente Y; Pérez-Sidelnikova D; García-Del Muro J; Viñals JM; Vidal A; Valdés-Mas R; Terribas E; López-Doriga A; Pujana MA; Capellá G; Puente XS; Serra E; Villanueva A; Lázaro C
EMBO Mol Med; 2015 May; 7(5):608-27. PubMed ID: 25810463
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.
Larsson AT; Bhatia H; Calizo A; Pollard K; Zhang X; Conniff E; Tibbitts JF; Rono E; Cummins K; Osum SH; Williams KB; Crampton AL; Jubenville T; Schefer D; Yang K; Lyu Y; Pino JC; Bade J; Gross JM; Lisok A; Dehner CA; Chrisinger JSA; He K; Gosline SJC; Pratilas CA; Largaespada DA; Wood DK; Hirbe AC
Neuro Oncol; 2023 Nov; 25(11):2044-2057. PubMed ID: 37246765
[TBL] [Abstract][Full Text] [Related]
11. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.
Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M
J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940
[TBL] [Abstract][Full Text] [Related]
12. RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST.
Chung MH; Aimaier R; Yu Q; Li H; Li Y; Wei C; Gu Y; Wang W; Guo Z; Long M; Li Q; Wang Z
Cell Oncol (Dordr); 2023 Oct; 46(5):1399-1413. PubMed ID: 37086345
[TBL] [Abstract][Full Text] [Related]
13. Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis.
González-Muñoz T; Di Giannatale A; García-Silva S; Santos V; Sánchez-Redondo S; Savini C; Graña-Castro O; Blanco-Aparicio C; Fischer S; De Wever O; Creus-Bachiller E; Ortega-Bertran S; Pisapia DJ; Rodríguez-Peralto JL; Fernández-Rodríguez J; Pérez-Portabella CR; Alaggio R; Benassi MS; Pazzaglia L; Scotlandi K; Ratner N; Yohay K; Theuer CP; Peinado H
Clin Cancer Res; 2023 Sep; 29(18):3744-3758. PubMed ID: 37432984
[TBL] [Abstract][Full Text] [Related]
14. Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo.
Schulte A; Ewald F; Spyra M; Smit DJ; Jiang W; Salamon J; Jücker M; Mautner VF
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102484
[TBL] [Abstract][Full Text] [Related]
15. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
[TBL] [Abstract][Full Text] [Related]
16. Characterizing T-cell dysfunction and exclusion signatures in malignant peripheral nerve sheath tumors reveals susceptibilities to immunotherapy.
Bhandarkar AR; Bhandarkar S; Babovic-Vuksanovic D; Parney IF; Spinner RJ
J Neurooncol; 2023 Sep; 164(3):693-699. PubMed ID: 37755632
[TBL] [Abstract][Full Text] [Related]
17. Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiation.
Magallón-Lorenz M; Fernández-Rodríguez J; Terribas E; Creus-Batchiller E; Romagosa C; Estival A; Perez Sidelnikova D; Salvador H; Villanueva A; Blanco I; Carrió M; Lázaro C; Serra E; Gel B
Hum Genet; 2021 Aug; 140(8):1241-1252. PubMed ID: 34059954
[TBL] [Abstract][Full Text] [Related]
18. Integrating analysis of proteome profile and drug screening identifies therapeutic potential of MET pathway for the treatment of malignant peripheral nerve sheath tumor.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Akiyama T; Kosako H; Yoshida A; Ohtori S; Kawai A; Kondo T
Expert Rev Proteomics; 2023; 20(4-6):109-119. PubMed ID: 37229542
[TBL] [Abstract][Full Text] [Related]
19. Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors.
Chau V; Lim SK; Mo W; Liu C; Patel AJ; McKay RM; Wei S; Posner BA; De Brabander JK; Williams NS; Parada LF; Le LQ
Cancer Res; 2014 Jan; 74(2):586-97. PubMed ID: 24285727
[TBL] [Abstract][Full Text] [Related]
20. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Lopez G; Torres K; Liu J; Hernandez B; Young E; Belousov R; Bolshakov S; Lazar AJ; Slopis JM; McCutcheon IE; McConkey D; Lev D
Cancer Res; 2011 Jan; 71(1):185-96. PubMed ID: 21084276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
